Differentiated Thyroid Cancer Clinical Trial
Official title:
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
The purpose of the study is to find out if the small dose of radioiodine, that is used for the dosimetry study on patients with differentiated thyroid cancer, may stun the cancer cells and make the thyroid cancer treatment less effective.
This study plans to learn more about a medical problem called thyroid stunning. Thyroid
stunning is a temporary decrease in the function of thyroid cells after small doses of
radioiodine, a radioactive drug that is commonly used to treat thyroid cancer. Thyroid
stunning can be an important medical problem in patients who have thyroid cancer that has
spread beyond the thyroid gland (metastases). In patients with thyroid cancer metastases,
some researchers believe it is good to give the maximum safe dose of radioiodine in order to
have the greatest chance of destroying the cancer. The maximum safe dose is the highest dose
of radioiodine that a patient can safely receive, and this dose is unique to each person.
This special personalized dose is determined by first doing a dosimetry study. Dosimetry
study is a planning study that calculates the safest dose that the patient can receive.
Currently, it is not known whether the small dose of radioiodine that is used for the
dosimetry study may stun the cancer cells and make the thyroid cancer treatment less
effective.
There are two important types of radioiodine. I-123 is a form of radioiodine that is used to
take pictures of the thyroid gland. I-131 is a form of radioiodine that is used to treat
thyroid cancer. It is hoped that this study will produce important information that may be
the first step in resolving the thyroid stunning question. Investigators will use I-123, a
form of iodine that is currently not known to cause thyroid stunning, before thyroid cancer
treatment with I-131. Investigators will try to prove that I-123 does not cause thyroid
stunning and does not make the thyroid cancer treatment less effective.
Patients are being asked to be in this research study because they have differentiated
thyroid cancer, and they have no evidence of thyroid cancer that has spread to the other
parts of their body. As a result, those patients thyroid cancer treatment with radioiodine
will be a smaller amount than what is needed to treat patients with thyroid cancer that has
spread to other parts of the body. Thyroid stunning is not a medical problem for patients
like these. However, by participating in this study, the information investigators gather
from those patients treatment of thyroid cancer may help those patients with thyroid cancer
metastases.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02870569 -
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT01876784 -
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
| Completed |
NCT04971473 -
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
|
Phase 3 | |
| Recruiting |
NCT04964284 -
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
| Recruiting |
NCT05078853 -
Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
|
||
| Active, not recruiting |
NCT03690388 -
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
|
Phase 3 | |
| Recruiting |
NCT02638077 -
Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
|
N/A | |
| Recruiting |
NCT01700699 -
Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
|
N/A | |
| Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
| Recruiting |
NCT04563780 -
The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
|
||
| Completed |
NCT03191643 -
PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer
|
N/A | |
| Active, not recruiting |
NCT04447183 -
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
|
Phase 2 | |
| Active, not recruiting |
NCT01263951 -
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
|
Phase 2 | |
| Active, not recruiting |
NCT04940052 -
Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
|
Phase 3 | |
| Recruiting |
NCT04880798 -
Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer
|
N/A | |
| Recruiting |
NCT05789667 -
Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
|
||
| Recruiting |
NCT05660954 -
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
|
Phase 2 | |
| Completed |
NCT00295763 -
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
|
Phase 3 | |
| Recruiting |
NCT04321954 -
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
|
Phase 2 |